New River names new VP of sales

Share this article:
New River Pharmaceuticals named James Shaffer as VP of sales and marketing to oversee the anticipated launch of the company's attention deficit-hyperactivity disorder (ADHD) drug Vyvanse.
Shaffer joins New River from Prestwick Pharmaceuticals. Shaffer served as senior director, commercial operations at Prestwick since 2004. Prior to that, he worked at Intermune as national sales director.

New River will co-market Vyvanse along with Shire. Vyvanse is expected to follow in the footsteps of Shire's ADHD market-leading Adderall XR but is formulated to be harder to abuse.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...